Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
The article discusses India's ongoing intermediate liability framework and the recent challenges posed by copyright enforcement. The Delhi High Court has sought clarity on these matters from Meta, marking a pivotal moment in digital copyright law.
The Delhi High Court has addressed critical aspects of pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents, revisiting coverage disclosure and the therapeutic efficacy threshold under Section 3(d).
The Delhi High Court's ruling in Saregama v. Ilaiyaraaja clarifies the evidentiary threshold necessary to support interim injunctions in copyright disputes, addressing assignment validity and digital rights issues.
The Delhi High Court's decision in Home Box Office Inc. v. Streamzy.To addresses the balance between combating online piracy and the limitations of website blocking under Section 79 of the IT Act. The ruling seeks to define the role of intermediaries more clearly.
The Delhi High Court's decision in Saregama v. Ilaiyaraaja has shed light on the evidentiary threshold for establishing copyright ownership in interim injunction applications. The ruling addresses the balance between evidence required and potential irreparable injury.
The Delhi High Court addressed key issues in pharmaceutical patent law regarding coverage disclosure and therapeutic efficacy requirements under Section 3(d) in Intra Cellular Therapies v. Controller of Patents. The ruling highlights complexities in how patent claims are assessed in India.
The Delhi High Court’s ruling in Home Box Office Inc. v. Streamzy.To provides critical insights on dynamic injunctions and their impact on copyright infringement strategies amid online piracy challenges.
The Delhi High Court's decision in Saregama v. Ilaiyaraaja clarifies the evidentiary standards for obtaining interim injunctions. This ruling is pivotal for copyright owners seeking protection during ongoing disputes.
The Delhi High Court in Intra Cellular Therapies v. Controller of Patents addressed pivotal issues in pharmaceutical patent law concerning disclosure in genus-species claims and therapeutic efficacy under Section 3(d). The ruling highlights both advancements and shortcomings in the Court's analysis relevant for practitioners in patent law.
The Delhi High Court's ruling in *Home Box Office Inc. v. Streamzy.To* provides insights into the dynamics of injunctions and web blocking, framing the ongoing legal discourse on copyright and digital rights.
The Delhi High Court, in *Intra Cellular Therapies v. Controller of Patents*, discussed key issues in pharmaceutical patent law, particularly around Section 3(d) and the coverage disclosure distinction in genus-species claims. The court’s interpretation raises questions about novelty and inventive step.
The Madras High Court's examination of Section 107A in the Novartis AG case provides greater clarity on the evidentiary standards for the Bolar exemption, raising concerns about the burdens on manufacturers that could undermine the exemption's intent.